Barry is Bessor’s Founder and Chair of its Board of Directors. Barry has founded and led highly successful drug discovery and development organizations in start-up and large pharmaceutical environments for nearly 40 years. He has built value around the companies he has led through numerous strategic transactions, including alliances with major pharma companies, such as Eli Lilly, Pfizer, Wyeth and Bristol Myers Squibb as well as M&A. Companies he has co-founded and or led as CEO include: Myco/Chemgenics (acquired by Millennium Pharmaceuticals); New Chemical Entities (acquired by Albany Molecular); and Fibrogen. Earlier in his career, he held senior research positions at Smith, Kline & French, where he was a Vice President, and the Roche Institute of Molecular Biology. Barry holds a BS degree in Pharmacy from Northeastern University and a PhD in Pharmacology from the University of California San Francisco.